NRx is excited about the most recent report published by the Israeli Institute of Biological Research on the BriLife® vaccine. The scientific report shows serologic response against the Omicron variant in patients vaccinated during the phase 2 clinical trial of BriLife® against Sars-CoV-2 coronavirus. Ten of 13 vaccinated subjects demonstrated detectable neutralizing antibody against Omicron. […]
As reported last night in the Times of Israel, the former Director of the Israel Institute for Biological Research (IIBR) disclosed that the BriLife™ Vaccine has shown initial signs of effectiveness against the Omicron variant. This is the information that caused NRx to advise the public that we are moving towards a vanguard trial of […]
Yesterday, the Israel Institute for Biological Research (IIBR) announced that it is currently studying the new Omicron variant of the SARS-CoV-2 to assess the extent to which this variant is neutralized by antibodies produced by the BriLife™ COVID-19 vaccine.
Dose-Confirmatory Trial Follows Successful Phase 2a Trial Preclinical and Early Human Data Indicate BriLife™ May Confer Enhanced Immunity Against Delta variant RADNOR, Pa., Aug. 9, 2021 /PRNewswire/ — NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage, global biopharmaceutical company today announced it is initiating a phase 2b dose-confirmatory trial of the BriLife™ vaccine against COVID-19 in the Nation of Georgia. The vaccine […]
NRx Pharmaceuticals Announces Partnership with the Israel Institute for Biological Research to Complete Development and Commercialization of BriLife™ COVID Vaccine